Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer
May 28 2019 - 6:50AM
Intellia Therapeutics,
Inc., (NASDAQ:NTLA) has named Laura Sepp-Lorenzino, Ph.D., as its
new executive vice president and chief scientific officer. Dr.
Sepp-Lorenzino brings decades of leadership and research and
development experience, and joins Intellia to head its drug
research organization. Andrew Schiermeier, Ph.D., executive vice
president of development and corporate strategy, will continue to
lead the drug development organization.
“We are very pleased that Dr. Sepp-Lorenzino has joined the
Intellia team to help us implement our full-spectrum genome editing
strategy,” said Intellia President and Chief Executive Officer John
Leonard, M.D. “Laura is a highly regarded scientific leader in the
biopharmaceutical and biotech industries with an impressive track
record in delivering new innovations to the clinic. She has led
premier scientific organizations with groundbreaking work in
nucleic acid therapies, infectious diseases, rare diseases and
cancer. We welcome her deep expertise in genomics, cellular and
molecular biology, and preclinical and clinical drug discovery and
development.”
Dr. Sepp-Lorenzino’s Professional and Academic
Credentials
Dr. Sepp-Lorenzino’s career spans more than three decades in the
biopharmaceutical industry and academia. She joins Intellia from
Vertex Pharmaceuticals, Inc., where she was vice president, head of
Nucleic Acid Therapies, Research Leadership, and member of the
External Innovation team. At Vertex, she focused on developing an
integrated nucleic acid therapies strategy through internal
programs and key research collaborators. Prior to working at
Vertex, Dr. Sepp-Lorenzino was vice president,
entrepreneur-in-residence and head of the Hepatic Infectious
Disease Strategic Therapeutic Area at Alnylam Pharmaceuticals, Inc.
During her time at Alnylam, she developed and implemented the
company’s hepatic infectious disease strategy, championed
extra-hepatic oligonucleotide delivery, helped secure long-term
research partnerships and built a strong pipeline of RNA
interference (RNAi) drug candidates. Dr. Sepp-Lorenzino spent 14
years at Merck & Co., Inc., where she held numerous leadership
and laboratory positions in the drug discovery organization. At
Merck Research Laboratories, she became an industry pioneer in
advancing RNAi as a novel therapeutic modality.
Dr. Sepp-Lorenzino received her postdoctoral training and was
assistant lab member at Memorial Sloan-Kettering Cancer Institute’s
prestigious Department of Medicine and Program in Molecular and
Cell Biology. She completed both her master’s degree and doctorate
in biochemistry at New York University, and received her
professional degree in biochemistry from the University of Buenos
Aires, School of Pharmacy and Biochemistry.
She holds professional affiliations with key scientific
organizations, including the Oligonucleotide Therapeutics Society,
the American Society for Gene and Cell Therapy, and the European
Society of Gene and Cell Therapy, as well as a number of
professional societies. Dr. Sepp-Lorenzino has given more than 30
lectures since 2011 and published more than 80 journal articles. As
a leading mind in the field, she has been a peer reviewer for more
than 11 scientific journals, including Nature Biotechnology.
“Having the opportunity to join the Intellia team when the
company is on the cusp of entering clinical trials with a
CRISPR/Cas9 therapy is exciting,” said Dr. Sepp-Lorenzino. “The
explosive growth of genome editing promises new ways to address
serious and rare genetic diseases. I look forward to making many
contributions to the company’s R&D programs and complementing
its talented scientists with my experience.”
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology
has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course, and through improved cell therapies that can treat cancer
and immunological diseases by replacing patients’ diseased cells.
The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more
about Intellia Therapeutics and CRISPR/Cas9
at intelliatx.com and follow us on Twitter
@intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements”
of Intellia Therapeutics, Inc. (“Intellia”) within the meaning
of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, express
or implied statements regarding Intellia’s ability to advance and
expand the CRISPR/Cas9 technology to develop into human therapeutic
products, as well as our intellectual property portfolio; our
ability to achieve stable or effective genome editing; our ability
to administer our CRISPR/Cas9 product candidates; the potential
timing and advancement of our preclinical studies, including
continuing non-human primate studies for our ATTR program and other
programs, and clinical trials; the timing and potential achievement
of milestones to advance our pipeline, including nominating
development candidates and filing INDs; the modularity of our
platform and our ability to replicate or apply results achieved in
our preclinical studies, including those in our ATTR and AML
programs, in any future studies, including human clinical trials;
the potential development of our proprietary LNP/AAV hybrid
delivery system to advance our complex genome editing capabilities;
our ability to initiate and conduct successful IND-enabling
toxicology studies of NTLA-2001, our lead ATTR development
candidate, and subsequently submitting an IND application in 2020
that will be accepted by the regulatory agencies; our growth as a
company and the anticipated contribution of the members of our
board of directors and our executives to our operations and
progress; the impact of our collaborations on our development
programs; the potential timing of regulatory filings regarding our
development programs; our expectations regarding our uses of
capital, expenses, future accumulated deficit and other financial
results during the first quarter of 2019; and our ability to fund
operations into the first half of 2021.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks
related to Intellia’s ability to protect and maintain our
intellectual property position; risks related to Intellia’s
relationship with third parties, including our licensors; risks
related to the ability of our licensors to protect and maintain
their intellectual property position; uncertainties related to the
initiation and conduct of studies and other development
requirements for our product candidates; the risk that any one or
more of Intellia’s product candidates will not be successfully
developed and commercialized; the risk that the results of
preclinical studies will not be predictive of future results in
connection with future studies; and the risk that Intellia’s
collaborations with Novartis or Regeneron or its
other collaborations will not continue or will not be
successful. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Intellia’s actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk
Factors” in Intellia’s most recent annual report on Form 10-K as
well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with
the Securities and Exchange Commission. All information in
this press release is as of the date of the release,
and Intellia undertakes no duty to update this information
unless required by law.
Intellia Contacts:
Media:
Jennifer Mound Smoter |
Senior Vice President |
External Affairs & Communications |
+1 857-706-1071 |
jenn.smoter@intelliatx.com |
|
Lynnea Olivarez |
Associate Director |
External Affairs & Communications |
+1 956-330-1917 |
lynnea.olivarez@intelliatx.com |
|
Investors: |
|
Lina Li |
Senior Manager |
Investor Relations |
+1 857-706-1612 |
lina.li@intelliatx.com |
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024